Buscador de publicacions

Publicacions

  • Janin M, Ortiz-Barahona V, de Moura MC, Martínez-Cardús A, Llinàs-Arias P, Soler-Vila M, Nachmani D, Pelletier J, Schumann U, Calleja-Cervantes ME, Moran S, Guil S, Bueno-Costa A, Piñeyro D, Perez-Salvia M, Rosselló-Tortella M, Piqué L, Bech-Serra JJ, De La Torre C, Vidal A, Martínez-Iniesta M, Martín-Tejera JF, Villanueva A, Arias A, Cuartas I, Aransay AM, Morales-La Madrid A, Carcaboso AM, Santa-María López V, Mora J, Fernandez AF, Fraga MF, Aldecoa I, Pedrosa L, Graus F, Vidal N, Martínez-Soler F, Tortosa A, Carrato C, Balañá C, Boudreau MW, Hergenrother PJ, Kötter P, Entian KD, Hench J, Frank S, Mansouri S, Zadeh G, Dans PD, Orozco M, Thomas G, Blanco S, Seoane J, Preiss T, Pandolfi PP and Esteller M.

    Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

    ACTA NEUROPATHOLOGICA . 138(6): 1053-1074. Nº de cites: 123

    [doi:10.1007/s00401-019-02062-4]

  • Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M, Solit DB, Berger MF, Hyman DM, Lacouture ME, Erickson C, Saganty R, Ki M, Dunkel IJ, Santa-María López V, Mora J, Haroche J, Emile JF, Decaux O, Geissmann F, Savvides SN, Drilon A, Diamond EL and Abdel-Wahab O.

    Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

    NATURE MEDICINE . 25(12): 1839-1842. Nº de cites: 129

    [doi:10.1038/s41591-019-0653-6]

  • Xu L, Pierce JL, Sánchez A, Chen KS, Shukla AA, Fustino NJ, Stuart S, Bagrodia A, Krailo MD, Shaikh F, Billmire D, Pashankar F, Bestrashniy J, Wolter Oosterhuis J, Biermann K, Gillis AJM, Stoop J, Xie Y, Teot L, Mora J, Poyter JN, Rakheja D, Looijenga LHJ, Draper BW, Lindsay Frazier A and Armatruda JF.

    Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumours of childhood and adolescence

    EUR UROL SUPPL . 18(4): 13-14.

    [doi:10.1016/S1569-9056(19)32491-1]

  • Garcia-López M, Rodriguez-Hernandez CJ, Mateo-Lozano S, Pérez-Jaume S, Gonçalves-Alves E, Lavarino C, Mora J and de Torres C.

    Parathyroid hormone-like hormone plays a dual role in neuroblastoma depending on PTH1R expression

    MOLECULAR ONCOLOGY . 13(9): 1959-1975. Nº de cites: 9

    [doi:10.1002/1878-0261.12542]

  • Mora J, Valero M, DiCristina C, Jin M, Chain A and Bickham K.

    Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients

    PEDIATRIC BLOOD & CANCER . 66(6): . Nº de cites: 8

    [doi:10.1002/pbc.27690]

  • Carvalho D, Taylor KR, Gene-Olaciregui N, Molinari V, Clarke M, Mackay A, Ruddle R, Henley A, Valenti M, Hayes A, Brandon AH, Eccles SA, Raynaud F, Boudhar A, Monje M, Popov S, Moore AS, Mora J, Cruz-Martínez O, Vinci M, Brennan PE, Bullock AN, Carcaboso AM and Jones C.

    ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

    Communications Biology . 2: 156-156. Nº de cites: 67

    [doi:10.1038/s42003-019-0420-8]

  • Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo H, Ordóñez JL, Dominguez-Hormaetxe S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frias MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler KL, Seifert O, Kontermann RE, Pfizenmaier K, Simon L, Fabre M, Carcaboso AM, Ludwig JA and de Álava E.

    Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma

    CLINICAL CANCER RESEARCH . 25(7): 2228-2240. Nº de cites: 30

    [doi:10.1158/1078-0432.CCR-18-0936]

  • Guenther LM, Dharia NV, Ross L, Saur Conway A, Robichaud AL, Catlett JL, Wechsler C, Frank ES, Goodale AB, Church AJ, Tseng YY, Guha R, McKnight C, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F and Stegmaier K.

    A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

    CLINICAL CANCER RESEARCH . 25(4): 1343-1357. Nº de cites: 61

    [doi:10.1158/1078-0432.CCR-18-0372]

  • Pascual-Pastó G, Bazan-Peregrino M, Gene-Olaciregui N, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa MG, Paco-Mercader S, Vilà-Ubach M, Cuadrado-Vilanova M, Castillo H, Botteri G, García-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell-Burriel M, Roldan-Molina M, König A, Suñol M, Claverol J, Lavarino C, de Torres C, Fu L, Radvanyi F, Munier FL, Català-Mora J, Mora J, Alemany R, Cascallo M, Chantada G and Carcaboso AM.

    Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

    SCIENCE TRANSLATIONAL MEDICINE . 11(476): 9321. Nº de cites: 76

    [doi:10.1126/scitranslmed.aat9321]

  • Reichardt P, Tabone MD, Mora J, Morland B and Jones RL.

    Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling

    FUTURE ONCOLOGY . 14(25): 2663-2676. Nº de cites: 109

    [doi:10.2217/fon-2018-0210]